Pneumococcal Glycoconjugate Vaccine Composition for Emerging Serotypes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pneumococcal vaccines like PREVNAR 13® do not provide adequate protection against a range of Streptococcus pneumoniae serotypes, and there is a need for immunogenic compositions that induce an immune response against these serotypes, particularly in children under 2 years old and in regions with emerging antibiotic resistance.
Innovation Solution
Development of novel immunogenic compositions comprising glycoconjugates from serotypes 6C, 7C, 9N, 15A, 15B, 15C, 16F, 17F, 20, 23A, 23B, 31, 34, 35B, and 38, which are conjugated to carriers like CRM197 or TT, and can be combined with additional antigens and adjuvants to enhance immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing pneumococcal vaccines (PREVNAR 13®) are used, then coverage for 13 serotypes is provided, but protection against emerging serotypes (6C, 7C, 9N, 15A, 15B, 15C, 16F, 17F, 20, 23A, 23B, 31, 34, 35B, 38) is insufficient
Solution Approach 1:
The vaccine is segmented into multiple serotype-specific glycoconjugate components, each targeting a specific pneumococcal serotype. The composition includes separate conjugated capsular saccharide antigens for serotypes 6C, 7C, 9N, 15A, 15B, 15C, 16F, 17F, 20, 23A, 23B, 31, 34, 35B, and 38, allowing the vaccine to address multiple serotypes simultaneously while maintaining targeted immunity for each.
Solution Approach 2:
The vaccine formulation achieves multi-functionality by incorporating a broad spectrum of serotypes into a single immunogenic composition. The glycoconjugates are conjugated to carrier proteins (such as CRM197 or TT) to create a universal vaccine platform that can elicit immune responses against diverse pneumococcal serotypes, including those not covered by PREVNAR 13®.
2Adaptability or versatility
If more serotypes are included in the vaccine, then protection coverage increases, but formulation complexity increases
Solution Approach 1:
Multiple serotype-specific glycoconjugate components are merged into a single immunogenic composition. The capsular saccharide antigens from different serotypes are conjugated to carrier proteins and combined in one formulation, allowing simultaneous delivery of multiple antigens while maintaining a unified vaccine structure that simplifies administration.
Solution Approach 2:
The vaccine employs composite material structure by combining polysaccharide capsular antigens with carrier proteins to form glycoconjugates. This composite approach allows multiple serotype-specific antigens to be integrated into a cohesive molecular structure, facilitating stable formulation while maintaining the immunogenicity of each individual serotype component.
Data Source
AI summary
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.